Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: TheLixiLan JP-O2randomized clinical trial
Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: TheLixiLan JP-O2randomized clinical trial
复制标题
DOI：
10.1111/dom.14036
复制
发表时间：
2020-09-01
影响因子：
5.8
通讯作者：
Niemoeller, Elisabeth
中科院分区：
文献类型：
--
作者：
Terauchi, Yasuo;Nakama, Takahiro;Niemoeller, Elisabeth
目的 评估口服降糖药 (OAD) 控制不佳的日本 2 型糖尿病 (T2DM) 患者中，使用甘精胰岛素 / 利司那肽固定比例组合 (iGlarLixi) 与甘精胰岛素 U100 (iGlar) 进行 26 周治疗的疗效和安全性。材料和方法 这项 3 期、多中心、开放标签、1:1 随机、平行组研究比较了 iGlarLixi 和 iGlar 在 HbA1c ≥ 7.5% 的 T2DM 患者中的疗效
Aims To assess efficacy and safety of 26-week treatment with insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with insulin glargine U100 (iGlar) in Japanese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on oral antidiabetic drugs (OADs). Materials and Methods This phase 3, multicentre, open-label, 1:1 randomized, parallel-group study compared efficacy of iGlarLixi and iGlar in patients with T2DM, HbA1c of >= 7.5% to